A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

Description

It is a Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects with Advanced Solid Tumors

Conditions

Advanced Solid Tumor, NSCLC

Talk to us

Study Overview

On this page

Study Details

Study overview

It is a Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects with Advanced Solid Tumors

A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

Condition
Advanced Solid Tumor
Intervention / Treatment

-

Contacts and Locations

Lafayette

Horizon Oncology, Lafayette, Indiana, United States, 47905

San Antonio

Next Oncology, San Antonio, Texas, United States, 78229

Spokane

Summit Cancer Centers, Spokane, Washington, United States, 99216

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    Shanghai Huaota Biopharmaceutical Co., Ltd.,

    Yang Yang, MD/PHD, STUDY_DIRECTOR, Shanghai Huaota Biopharmaceutical Co., Ltd.

    Study Record Dates

    2024-08-01